| Literature DB >> 36040531 |
Wen Song1,2, Qingwen Shan3, Yue Qiu4, Xianyao Lin1, Chunhui Zhu5, Zhiqiang Zhuo6, Caihong Wang6, Jianning Tong7, Rui Li7, Chaomin Wan8, Yu Zhu8, Minxia Chen9, Yi Xu9, Daojiong Lin10, Shouye Wu10, Chunmei Jia11, Huiling Gao11, Junwen Yang12, Shiyong Zhao13, Mei Zeng14.
Abstract
Invasive Salmonella infections result in a significant burden of disease including morbidity, mortality, and financial cost in many countries. Besides typhoid fever, the clinical impact of non-typhoid Salmonella infections is increasingly recognized with the improvement of laboratory detection capacity and techniques. A retrospective multicenter study was conducted to analyze the clinical profiles and antimicrobial resistance patterns of invasive Salmonella infections in hospitalized children in China during 2016-2018. A total of 130 children with invasive Salmonella infections were included with the median age of 12 months (range: 1-144 months). Seventy-nine percent of cases occurred between May and October. Pneumonia was the most common comorbidity in 33 (25.4%) patients. Meningitis and septic arthritis caused by nontyphoidal Salmonella (NTS) infections occurred in 12 (9.2%) patients and 5 (3.8%) patients. Patients < 12 months (OR: 16.04) and with septic shock (OR: 23.4), vomit (OR: 13.33), convulsion (OR: 15.86), C-reactive protein (CRP) ≥ 40 g/L (OR: 5.56), and a higher level of procalcitonin (PCT) (OR: 1.05) on admission were statistically associated to an increased risk of developing meningitis. Compared to 114 patients with NTS infections, 16 patients with typhoid fever presented with higher levels of CRP and PCT (P < 0.05). The rates of resistance to ampicillin, sulfamethoxazole/trimethoprim, ciprofloxacin, and ceftriaxone among Salmonella Typhi and NTS isolates were 50% vs 57.3%, 9.1% vs 24.8%, 0% vs 11.2%, and 0% vs 9.9%, respectively. NTS has been the major cause of invasive Salmonella infections in Chinese children and can result in severe diseases. Antimicrobial resistance among NTS was more common.Entities:
Keywords: Children; China; Invasive nontyphoidal Salmonella; Typhoid fever
Mesh:
Substances:
Year: 2022 PMID: 36040531 PMCID: PMC9489584 DOI: 10.1007/s10096-022-04476-7
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 5.103
Fig. 1Seasonality of invasive Salmonella infections among inpatients by year
The clinical characteristics of patients with invasive Salmonella infections before administrated associated with meningitis
| Parameters | Total | Meningitis group | Non-meningitis group | |
|---|---|---|---|---|
| ( | ( | ( | ||
| Age (month), median (IQR) | 12 (8–20.25) | 4 (1–8) | 12 (9–21) | < 0.001* |
| Gender, male (%) | 77 (59.2) | 7 (58.3) | 70 (59.3) | 1.000 |
| Comorbidities (%) | 55 (42.3) | 6 (50.0) | 49 (41.5) | 0.571 |
| Length (days) of hospital stay, median (IQR) | 10 (7–15.25) | 28.5 (8.75–30.75) | 10 (6.75–14) | 0.025* |
| Fever (%) | 118 (90.8) | 12 (100) | 106 (89.8) | 0.602 |
| Fever duration (day), median (IQR) | 5 (2–7) | 3 (1.25–5.75) | 5 (2–7) | 0.116 |
| Septic shock (%) | 3 (2.3) | 2 (16.7) | 1 (0.8) | 0.022* |
| Rash (%) | 15 (11.5) | 0 (0) | 15 (12.7) | 0.358 |
| Cough (%) | 37 (28.5) | 1 (8.3) | 36 (30.5) | 0.177 |
| Respiratory distress (%) | 5 (3.8) | 1 (8.3) | 4 (3.4) | 0.389 |
| Tachypnea (%) | 8 (6.2) | 0 (0) | 8 (6.8) | 1.000 |
| Cyanosis (%) | 2 (1.5) | 1 (8.3) | 1 (0.8) | 0.177 |
| Vomit (%) | 11 (8.5) | 5 (41.7) | 6 (5.1) | 0.001* |
| Diarrhea (%) | 43 (33.1) | 1 (8.3) | 42 (35.6) | 0.103 |
| Convulsion (%) | 13 (10) | 6 (50) | 7 (5.9) | < 0.001* |
| Leukocyte < 4000 or > 15,000 count/mm3 (%) | 43(35) a | 6(50) | 37(33.3) a | 0.340 |
| Neutropenia (%) | 8 (6.5) a | 0 (0) | 8 (7.2) a | 1.000 |
| Platelet < 100,000 count/mm3 (%) | 12 (9.8) a | 1 (8.3) | 11 (9.9) a | 1.000 |
| CRP ≥ 40 g/L (%) | 35 (30.7) b | 8 (66.7) | 27 (26.5) b | 0.012* |
| PCT (μg/L), median(IQR) | 0.37 (0.14–2.08) c | 19.11 (1.97–42.31) d | 0.3 (0.13–1.56)e | < 0.001* |
| GPT > 40 U/L (%) | 44 (47.3) f | 6 (60) g | 38 (45.8) h | 0.509 |
| GOT > 40 U/L (%) | 62 (66.7) f | 5 (50) g | 57 (68.7)h | 0.292 |
CRP, C-reactive protein; PCT, procalcitonin; GPT, glutamic-pyruvic transaminase; GOT, glutamic-oxaloacetic transaminase
a7 cases were missing; b16 cases were missing; c31 cases were missing; d4 cases were missing; e27 cases were missing; f37 cases were missing; g2 cases were missing; h35 cases were missing
*P < 0.05
Risk factors for children with meningitis caused by Salmonella infection. Univariate analysis
| Variables | Meningitis group | Non-meningitis group | OR (95%CI) | |
|---|---|---|---|---|
| ( | ( | |||
| Age < 12 months | 11 (91.7) | 48 (40.7) | 16.04 (2–128.38) | 0.009* |
| Septic shock | 2 (16.7) | 1 (0.8) | 23.4 (1.95–281.05) | 0.013* |
| Vomit | 5 (41.7) | 6 (5.1) | 13.33 (3.25–54.68) | < 0.001* |
| Convulsion | 6 (50) | 7 (5.9) | 15.86 (4.05–62.11) | < 0.001* |
| CRP ≥ 40 g/L | 8 (66.7) | 27 (26.5)a | 5.56 (1.55–19.95) | 0.009* |
| PCT (μg/L) | 19.11 (1.97–42.31) b | 0.3 (0.13–1.56)c | 1.05 (1.01–1.1) | 0.013* |
a16 cases were missing; b4 cases were missing; c27 cases were missing
*P < 0.05
The surveillance cohort of invasive Salmonella infections stratified by Salmonella enterica serovars
| No. of cases | Jiangxi Provincial Children’s Hospital, no | Henan Children’s Hospital, no | West China Women’s and Children’s Hospital, no | Xiamen Children’s Hospital, no | Hainan Women and Children’s Medical Center, no | The First Affiliated Hospital of Guangxi Medical University, no | Guangzhou Women and Children’s Medical Center, no | Hangzhou Children’s Hospital, no | Qingdao Women and Children’s Hospital, no | The Forth Hospital of Baotou, no | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 | 2 | 0 | 1 | 0 | 0 | 6 | 1 | 1 | 0 | 0 | |
| 5 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | |
| NTS | |||||||||||
| Group B | 10 | 0 | 0 | 3 | 3 | 0 | 0 | 1 | 2 | 1 | 0 |
| Derby | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Typhimurium | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Group C | 8 | 2 | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Choleraesuis | 5 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group D | 11 | 0 | 0 | 6 | 0 | 1 | 0 | 3 | 0 | 1 | 0 |
| Enteritidis | 7 | 0 | 0 | 3 | 0 | 1 | 0 | 2 | 0 | 1 | 0 |
| Dublin | 4 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Group E | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Meleagridis | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other serovars | 82 | 40 | 32 | 3 | 1 | 3 | 1 | 0 | 1 | 0 | 1 |
S. Typhi, Salmonella Typhi; S. Paratyphi, Salmonella Paratyphi; NTS, nontyphoidal Salmonella
The clinical characteristics of invasive Salmonella infections stratified by Salmonella serovars
| Parameters | Total | Nontyphoidal | ||
|---|---|---|---|---|
| ( | ( | ( | ||
| Age (month), median (IQR) | 12 (8–20.25) | 30 (14.3–48.5) | 11.5 (8–16.5) | 0.001* |
| Gender, male (%) | 77 (59.2) | 11 (68.8) | 66 (57.9) | 0.408 |
| Comorbidities (%) | 55 (42.3) | 12 (75) | 43 (37.7) | 0.005* |
| Meningitis (%) | 12 (9.2) | 1 (6.3) | 11 (9.6) | 1.000 |
| Septic arthritis (%) | 5 (3.8) | 0 (0) | 5 (4.4) | 1.000 |
| Fever (%) | 118 (90.8) | 15 (93.8) | 103 (90.4) | 1.000 |
| Fever duration (day), median (IQR) | 5 (2–7) | 6 (3–11) | 4 (2–7) | 0.085 |
| Septic shock (%) | 3 (2.3) | 0 (0) | 3 (2.6) | 1.000 |
| Rash (%) | 15 (11.5) | 2 (12.5) | 13 (11.4) | 1.000 |
| Cough (%) | 37 (28.5) | 8 (50) | 29 (25.4) | 0.072 |
| Respiratory distress (%) | 5 (3.8) | 0 (0) | 5 (4.4) | 1.000 |
| Tachypnea (%) | 8 (6.2) | 1 (6.3) | 7 (6.1) | 1.000 |
| Cyanosis (%) | 2 (1.5) | 0 (0) | 2 (1.8) | 1.000 |
| Vomit (%) | 11 (8.5) | 2 (12.5) | 9 (7.9) | 0.625 |
| Diarrhea (%) | 43 (33.1) | 2 (12.5) | 41 (36) | 0.062 |
| Convulsion (%) | 13 (10) | 3 (18.8) | 10 (8.8) | 0.201 |
| Leukocyte < 4000 or > 15,000 count/mm3 (%) | 43 (35) a | 8 (53.3)b | 35 (32.4)c | 0.111 |
| Neutropenia (%) | 8 (6.5) a | 3 (20)b | 5 (4.6) c | 0.057 |
| Platelet < 100,000 count/mm3 (%) | 12 (9.8) a | 4 (26.7)b | 8 (7.4) c | 0.040* |
| CRP ≥ 40 g/L (%) | 35 (30.7) d | 10 (66.7)b | 25 (25.3)e | 0.003* |
| PCT (μg/L), median(IQR) | 0.37 (0.14–2.08) f | 1 (0.56–5.62) g | 0.29 (0.13–1.8) h | 0.013* |
| GPT > 40 U/L (%) | 44 (47.3) i | 5 (33.3) b | 39 (50) j | 0.236 |
| GOT > 40 U/L (%) | 62 (66.7) i | 9 (60) b | 53 (67.9) j | 0.550 |
a7 cases were missing; b1 case was missing; c6 cases were missing; d16 cases were missing; e15 cases were missing; f31 cases were missing; g3 cases were missing; h28 cases were missing; i37 cases were missing; j36 cases were missing
*P < 0.05
The distribution of Salmonella enterica serovars stratified by the sites of invasive Salmonella infections
| Blood, | Cerebrospinal fluid, | Joint fluid, | Bone aspirate, | |
|---|---|---|---|---|
| Total number, | 119 (100) | 9 (100) | 1 (100) | 1 (100) |
| 11 (9.2) | 0 (0) | 0 (0) | 0 (0) | |
| 4 (3.4) | 1 (11.1) | 0 (0) | 0 (0) | |
| NTS | 104 (87.4) | 8 (88.9) | 1 (100) | 1 (100) |
| Group B | 10 (8.4) | 0 (0) | 0 (0) | 0 (0) |
| Derby | 2 (1.7) | 0 (0) | 0 (0) | 0 (0) |
| Typhimurium | 3 (2.5) | 0 (0) | 0 (0) | 0 (0) |
| Group C | 8 (6.7) | 0 (0) | 0 (0) | 0 (0) |
| Choleraesuis | 5 (4.2) | 0 (0) | 0 (0) | 0 (0) |
| Group D | 9 (7.6) | 1 (11.1) | 1 (100) | 0 (0) |
| Enteritidis | 5 (4.2) | 1 (11.1) | 1 (100) | 0 (0) |
| Dublin | 4 (3.4) | 0 (0) | 0 (0) | 0 (0) |
| Group E | 2 (1.7) | 1 (11.1) | 0 (0) | 0 (0) |
| Meleagridis | 1 (0.8) | 0 (0) | 0 (0) | 0 (0) |
| Other serovars | 75 (63) | 6 (66.7) | 0 (0) | 1 (100) |
Resistance patterns of invasive Salmonella isolates to antimicrobial agents
| Antimicrobial drugs | Percentage resistance % (number of isolates resistant/number of isolates tested) | ||
|---|---|---|---|
| Nontyphoidal | |||
| Ampicillin | 50 (5/10) | 40 (2/5) | 57.3 (63/110) |
| Piperacillin | 50 (4/8) | NT | 45.3 (29/64) |
| Ampicillin/sulbactam | 20 (1/5) | NT | 54.7 (58/106) |
| Piperacillin/tazobactam | 0 (0/11) | NT | 2.8 (3/106) |
| Cefotaxime or ceftriaxone | 0 (0/11) | 20 (1/5) | 9.9 (11/111) |
| Ceftazidime | 0 (0/10) | 20 (1/5) | 7.2 (8/111) |
| Cefepime | 9.1 (1/11) | 0 (0/5) | 5.5 (6/110) |
| Aztreonam | 0 (0/11) | NT | 7.3 (8/109) |
| Gentamicin or tobramycin | 0 (0/5) | NT | 18.5 (20/108) |
| Amikacin | 0 (0/5) | NT | 10.5 (11/105) |
| Imipenem | 0 (0/11) | NT | 0 (0/108) |
| Meropenem | 0 (0/8) | NT | 0 (0/88) |
| Ertapenem | 0 (0/2) | 0 (0/5) | 0 (0/32) |
| Tetracycline | 0 (0/2) | NT | 32 (24/75) |
| Ciprofloxacin or levofloxacin | 0 (0/9) | 66.7 (2/3) | 11.2 (11/98) |
| Sulfamethoxazole/trimethoprim | 9.1 (1/11) | 20 (1/5) | 24.8 (27/109) |
| Chloramphenicol | 20 (1/5) | NT | 16 (12/75) |
| MDR | 0 (0/11) | 20 (1/5) | 22.5 (25/111) |
NT, not test; MDR, multidrug resistance